Eastern Biotech offers a novel, noninvasive, DNA-based reference laboratory test for 4 well-validated genetic risk markers for type 2 diabetes- including TCF7L2 gene. This helps identify patients at increased risk of developing type 2 diabetes to help patients and physicians take early steps to prevent disease before it starts.

Physicinas may work more intensively with higher-risk patients to encourage lifestyle changes and patients in turn may be more motivated to comply.

1. Detects SNPs in TCF7L2, CDKAL1, CDKN2A, and PPARG genes that confer up to a 2.2 fold increased risk for type 2 diabetes comapred to the general population

2. Overweight prediabetics with a high-risk genetic profile have 50-7-% absolute risk of converting to type 2 diabetes within 3-4 years

3. 36% of patients positive for TCF7L2 marker react to sulfonylurea treatment compared to 62% who were negative for the test

4. Physicians can identify test-positive patients, who accoount for about 20% of type 2 diabetes, to determine whether alternative therapies are more appropriate

1. Order through our online payment section by clicking the button next to the test.

2. A staff from Eastern Biotech will contact you and provide all necessary information.

3. A DNA cheek swab sampling kit’ will be sent out to you my courier whereby you will be asked for a sample of both persons requiring testing. Our courier will collect the sample from your home/office.

4. Your sample will be processed at our affiliate laboratory and the report will be delivered to you by email and also by post.

5. Reporting: The DNA of both individuals is cross matched using sophisticated DNA analysis techniques, and a report is sent out to you.

Top

deCODE AF^TM is the first and only genetic test that offers insight into an individual's likelihood of having atrial fibrillation (AF)- a common but difficult-to-detect cause of ischemic stroke. Even when the ECG is negative, deCODE AF^TM test helps you identify at-risk AF patients for anticoagulant therapy.

1. 5.7% to 14.3% of hospitalized patients discharged with stroke of unknown etiology are likely to have intermittent AF missed by routine cardiac monitoring

2. Current guidelines recommend that ischemic stroke patients without confirmed AF be discharged on antiplatelet medications rather than warfarin

3. Antiplatelet agnets have minimal effcet on reducing stroke rates in AF - about 20% Vs 70% for warfarin

1. Order through our online payment section by clicking the button next to the test.

2. A staff from Eastern Biotech will contact you and provide all necessary information.

3. A DNA cheek swab sampling kit’ will be sent out to you my courier whereby you will be asked for a sample of both persons requiring testing. Our courier will collect the sample from your home/office.

4. Your sample will be processed at our affiliate laboratory and the report will be delivered to you by email and also by post.

5. Reporting: The DNA of both individuals is cross matched using sophisticated DNA analysis techniques, and a report is sent out to you.

Top

deCODE Breast Cancer™ is a DNA-based test for multiple risk factors shown to confer risk for the common form of breast cancer. The test identifies 7 genetic variants associated with a highre likelihood of developing breast cancer independent of family history.

This offers physicans the opportunity to begin advanced screening or initiate early treatment in those who are at increased risk.

1. The test multiplies the individual risk markers to create a genetic proifile that defines the relative risk of developing breast cancer, ranging from 0.4-(no risk variants) to approximately 4-fold (all 7 risk variants) compared with the general population

2. Genetic risk defined by the test is independent of convetional risk factors for breast cancer, including family history, which are used to determine which higher-risk women benefit from more intensive management to detect or prevent breast cancer

3. Patients with a higher risk (>20% lifetime risk) may benefit from more intensive screening with magnetic resonance imaging (MRI) in addition to routine mammography as recommended

4. Women under 60 years of age with a higher genetic risk may be candidates for preventive treatment

5. Some of the markers in the test modulate the lifetime risk for early breast cancer in BRCA1 and BRCA2 mutation carriers

1. Order through our online payment section by clicking the button next to the test.

2. A staff from Eastern Biotech will contact you and provide all necessary information.

3. A DNA cheek swab sampling kit’ will be sent out to you my courier whereby you will be asked for a sample of both persons requiring testing. Our courier will collect the sample from your home/office.

4. Your sample will be processed at our affiliate laboratory and the report will be delivered to you by email and also by post.

5. Reporting: The DNA of both individuals is cross matched using sophisticated DNA analysis techniques, and a report is sent out to you.

Top

Eastern Biotech offers the first genetic test to measure multiple markers of prostate cancer risk, independent of family history. The test identifies 8 genetic variants that are associated with increased risk of prostate cancer. Positive results carry relative risks ranging from 0.33 to over 6-fold compared to the general population.

1. About 20% of the general population has a combination of variants that carry a relative risk of 1.7, 10% carry a 2-fold relative risk, and 1% carry a >3-fold relative risk. For example, a 2-fold risk in while males trasnlates t a lifetime risk of 32% (2X16% baseline risk)

2. Risk is independent of family history, which is the only other risk factor for prostate cancer in white patients. Risk due to family history may be multiplied by risk from the genetic profile

3. Two of the markers in particular also offer additional insight into the aggressiveness of the disease

1. Order through our online payment section by clicking the button next to the test.

2. A staff from Eastern Biotech will contact you and provide all necessary information.

3. A DNA cheek swab sampling kit’ will be sent out to you my courier whereby you will be asked for a sample of both persons requiring testing. Our courier will collect the sample from your home/office.

4. Your sample will be processed at our affiliate laboratory and the report will be delivered to you by email and also by post.

5. Reporting: The DNA of both individuals is cross matched using sophisticated DNA analysis techniques,
and a report is sent out to you.

Top

deCODE Glaucoma™ is a reference laboratory DNA test for assessing an inherited risk factor for exfoliation glaucoma, a major subtype of the group of eye disorders termed Glaucoma. The test detects versions of markers called SNPs (single nucleotide polymorphisms) – a one letter variation in the sequence of the genome, more specifically on chromosome 15 - that deCODE has linked to an increased risk of exfoliation glaucoma.

Research has shown two sequence variants in a gene called LOXL1 that significantly increase the risk of developing exfoliation glaucoma. The effect is thought to be through what is called exfoliation syndrome which is characterized by accumulation of abnormal microfibrillar deposits that line the aqueous bathed surfaces of the anterior segment of the eye.

1. According to deCODE’s research the effect of the identified genetic risk variants seem to be in addition to and independent of other known risk factors such as intraocular pressure and age. This means that even though at this point in time there is no known remedy or actions that can be specifically taken to counteract the genetic risk associated with the LOXL1 variants, the overall risk for vision loss as a consequence of undetected exfoliation glaucoma may be decreased through frequent eye exams and physician recommended interventions.


2. Independent of the family history for glaucoma knowing ones genetic make-up in regard to deCODE’s genetic exfoliation glaucoma risk markers is relevant since they may be part of the familial risk or an addition to it.


3. The deCODE Glaucoma™ test therefore offers a new factor and added weight to the analysis of an individual’s risk for glaucoma which may help the individual and his/her physician to decide on future monitoring,
prevention and/or specific treatments.

1. Order through our online payment section by clicking the button next to the test.

2. A staff from Eastern Biotech will contact you and provide all necessary information.

3. A DNA cheek swab sampling kit’ will be sent out to you my courier whereby you will be asked for a sample of both persons requiring testing. Our courier will collect the sample from your home/office.

4. Your sample will be processed at our affiliate laboratory and the report will be delivered to you by email and also by post.

5. Reporting: The DNA of both individuals is cross matched using sophisticated DNA analysis techniques,
and a report is sent out to you.

Top